Clinical Laboratories

Chantilly, VA, United States

Clinical Laboratories

Chantilly, VA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | April 19, 2017
Site: www.businesswire.com

NASHVILLE, Tenn.--(BUSINESS WIRE)--Former Santa Rosa Consulting and InfoPartners senior executive James “Butch” Baxter has joined healthcare IT software communications firm MEDarchon, officials announced today. “ Butch’s rich background in healthcare business development – particularly within the healthcare IT management and consulting space – adds a vital and exciting dimension to our team,” says Jim Sohr, MEDarchon board chairman. “ We look forward to him leading our great bench of professionals and guiding our emerging company to the next level.” Prior to joining MEDarchon, Baxter was Senior Vice President of Franklin, Tennessee-based Santa Rosa Consulting. In 2012, Santa Rosa acquired Nashville-based InfoPartners where Baxter had enjoyed a significant career in business development and strategic management relationships. In addition to information technology, Baxter’s deep experience in healthcare includes positions in the CRO and clinical lab spaces – with ClinTrials Research, Inc. and SmithKline Beecham Clinical Laboratories, respectively – and in the managed care sector with American Medical Plan. “ Since its founding by W. Baxter Webb in 2013, MEDarchon has attracted a first-rate team of bright minds focused on developing best-in-class software to improve patient safety and communication,” says Baxter. “ Our team is driven by a desire to improve both the provider and patient experience by enhancing their communication and reducing hand-off inefficiencies. “ Bottom-line: We want to make the hospital experience a little less stressful for everyone.” Webb, MEDarchon’s founder and a board member, will assume the Chief Strategy Officer role to continue developing, facilitating and driving key strategic initiatives. MEDarchon is a next-generation healthcare communications software solution for physicians, nurses and other healthcare providers. Its signature product, QUARC, enhances paging and texting communication, workflow and patient safety for physicians, nurses and other healthcare providers. Designed by clinicians and administrators, QUARC’s functionality, usability, and big data analytics were created to prevent medical errors, improve organizational efficiency, and provide an unmatched level of security. The company is affiliated with POWERED HEALTH, a Nashville-based venture-support company majority-owned by Chairman/CEO Jim Sohr. Powered Health companies are joined by a guiding mission to provide proactive software and service solutions across the full continuum of care. We are all on a mission to change the business of healthcare through proactive cloud-based technology and enhanced service solutions. We power a positive change in interoperability, revenue, engagement, and compliance. Powered Health companies are helping hospitals and providers automate clinical and business processes that have historically been manually driven by unlocking the power of the data housed in EHRs to deliver better outcomes in patient care and patient safety at a lower cost. Together we are changing the business of healthcare.


News Article | May 4, 2017
Site: www.businesswire.com

BURLINGTON, N.C. & RENTON, Wash. & ENGLEWOOD, Colo.--(BUSINESS WIRE)--LabCorp® (NYSE:LH) has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services (Providence) and Catholic Health Initiatives (CHI). PAML, based in Spokane, Washington, is one of the nation’s premier medical reference laboratories and a healthcare solutions company. With the acquisition of PAML, LabCorp assumes PAML’s ownership interests in several joint ventures: Colorado Laboratory Services (CLS), Kentucky Laboratory Services (KLS), MountainStar Clinical Laboratories (MSCL), PACLAB Network Laboratories (PACLAB) and Tri-Cities Laboratory (TCL). In addition, PAML, as a LabCorp subsidiary, has acquired assets of Alpha Medical Laboratories (Alpha), a former PAML-affiliated joint venture, from its hospital owner. “For over three decades, LabCorp has focused on comprehensive, deeply-engaged relationships with health systems and hospitals,” said David P. King, chairman and chief executive officer, LabCorp. “The acquisition of PAML furthers this strategy and aligns LabCorp with Providence and CHI, two leading, innovative health systems, and deepens our engagement and growth opportunities with a number of important community-based hospitals across multiple states.” LabCorp’s acquisition of PAML represents the first step in completing the transaction. Through 2017 and into 2018, LabCorp will acquire the ownership interests in CLS, KLS and PACLAB from their hospital co-owners. The hospital partners in MSCL and in TCL continue to evaluate future options for their interests in those joint ventures, which may include a sale to LabCorp. PAML and the joint ventures serve customers in Colorado, Idaho, Kentucky, Montana, Oregon, Utah and Washington. Operations of each joint venture, including the menu of services provided, will remain substantially the same until the joint venture transition is complete and ownership has been transferred. There will be no significant changes to operations or services at PAML until all joint venture transactions are complete. The organizations have been working together to plan and implement a smooth, thoughtful transition that maintains continuity of services for patients, hospitals, clients and clinicians, and provides access to the additional capabilities of LabCorp, including access to clinical trials and research through Covance Drug Development, enhanced IT and data analytics, standardized testing platforms and broad patient access. “PAML and its joint ventures have successfully served our communities and many others for years, and we are proud of the high-quality service they have become known for,” said Mike Butler, president of operations, Providence St. Joseph Health. “Together, LabCorp and PAML will continue and expand delivery of high-quality health care services to our patients, hospitals, clients and clinicians.” Through and after the completion of the related joint venture transactions, Providence, CHI and the hospital joint venture owners will continue to provide all existing in-patient hospital laboratory services. PAML, along with LabCorp, will continue to provide the outreach testing services and reference laboratory services currently provided by PAML and the joint ventures. LabCorp and many of the health systems and hospitals that are partnered with PAML are exploring opportunities to collaborate on projects involving LabCorp’s differentiated capabilities. “As part of our mission, CHI is focused on building healthier communities,” said Kevin Lofton, CEO, Catholic Health Initiatives. “We are confident that LabCorp, as PAML’s new owner, will serve the best interests of all who have relied on us to meet their health care needs through comprehensive, high-quality laboratory services.” “This acquisition strengthens LabCorp’s relationships with anchor health systems and expands LabCorp’s geographic presence in important existing markets, allowing LabCorp to support each health system and its existing customers with expanded offerings,” said King. “It was made possible by the mutual commitment among all the parties to provide high-quality, compassionate care, and to improve the health and lives of the patients we serve and the communities where we operate.” Providence Health & Services is committed to improving the health of the communities it serves, especially for those who are poor and vulnerable. In 2016, Providence provided nearly $1.2 billion in community benefit to help meet the needs of its communities, both today and into the future. Providence Health & Services is a part of Providence St. Joseph Health, a family of organizations that includes 50 hospitals, 829 physician clinics, senior services, supportive housing and many other health and educational services. The health system and its partners employ more than 100,000 caregivers serving communities across seven states – Alaska, California, Montana, New Mexico, Oregon, Texas and Washington. Along with Saint Joseph Health, PSJH includes: in Texas, Covenant Health and Covenant Medical Group; in California, Facey Medical Foundation, Hoag Memorial Hospital Presbyterian and St. Joseph Heritage Healthcare; and in Washington, Kadlec Regional Medical Center, Pacific Medical Centers and Swedish Health Services. Catholic Health Initiatives, a nonprofit, faith-based health system formed in 1996 through the consolidation of four Catholic health systems, expresses its mission each day by creating and nurturing healthy communities in the hundreds of sites across the nation where we provide care. The nation’s third-largest nonprofit health system, Englewood, Colorado-based CHI operates in 18 states and comprises 104 hospitals, including four academic medical centers and major teaching hospitals as well as 30 critical-access facilities; community health-services organizations; accredited nursing colleges; home-health agencies; senior living communities; and other facilities and services that span the inpatient and outpatient continuum of care. In fiscal year 2016, CHI provided more than $1.1 billion in financial assistance and community benefit – a 13% increase over the previous year – for programs and services for the poor, free clinics, education and research. Financial assistance and community benefit totaled more than $2 billion with the inclusion of the unpaid costs of Medicare. The health system, which generated operating revenues of $15.9 billion in fiscal year 2016, has total assets of approximately $22.7 billion. LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of nearly $9.5 billion for 2016 through the contributions of 52,000 employees in approximately 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com. This press release contains forward-looking statements including with respect to estimated 2017 guidance and the impact of various factors on operating and financial results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.


LONDON, May 10, 2017 /PRNewswire/ -- Multiplex Assays Market by Type {Nucleic Acid-Based Multiplex Assays (Planar Nucleic Acid Assays and Bead-Based Nucleic Acid Assays), Protein-Based Multiplex Assays (Planar Protein Assays and Bead-Based Protein Assays), and Other Multiplex Assays}, Product {Multiplex Assay Reagents & Consumables, Multiplex Assay Accessories & Instruments, and Multiplex Assay Software & Services}, Technology {Multiplex PCR, Multiplex Protein Microarray, and Other Technologies}, Application {Companion Diagnostics, Research & Development (Drug Development and Biomarker Discovery & Validation), Clinical Diagnostics (Cancer, Infectious Diseases, Cardiac Diseases, Autoimmune Diseases, Alzheimer's Disease, and Other Diseases)}, and End User {Hospitals, Clinical Laboratories, Research Institutes, and Pharmaceuticals & Biotechnological Companies} - Global Opportunity Analysis and Industry Forecast, 2014-2022 Download the full report: https://www.reportbuyer.com/product/4883720/ Intraocular lenses (IOLs) are a type of ophthalmic implants, which are used in surgeries pertaining to eyes. IOLs are synthetic lenses implanted inside the eye that substitute the focusing power of a natural lenses, which are surgically removed. These are used to treat myopia, astigmatism, or cataracts. The global intraocular lens market generated $3,306 million in 2015, and is projected to reach $4,973 million by 2022, registering a CAGR of 7.0% during the study period. In terms of volume, the market is expected to grow at a CAGR of 7.1%. This is attributed to rise in geriatric population, increase in prevalence of cataract, and rise in initiatives taken by government to eliminate avoidable blindness. Moreover, rise in adoption of premium lens owing to their enhanced visual performance ensures reduced rates of astigmatism, thus supplementing the growth of the market. However, unfavorable reimbursement scenario for premium lens and postoperative complications such as refractive errors are expected to restrain the market growth. The intraocular lens market is segmented based on type, material, end user, and geography. On the basis of type, the market is bifurcated into monofocal and premium intraocular lens. The premium intraocular lens is sub-segmented into toric, multifocal, accommodating, and others (blue light filtering, phakic, and aspheric intraocular lens). By material, the market is categorized into polymethylmethacrylate (PMMA), silicone, and hydrophobic acrylic. According to end user, it is divided into hospitals, ambulatory surgical centers, ophthalmology clinics, and eye research institutes. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Prominent players adopted product development and product launches & approvals as their key developmental strategies to expand their product portfolio. For instance, in July 2016, Abott Medical Optics (now acquired by Johnson & Johnson) received FDA approval for the use of Tecnis Symfony Intraocular lenses for the treatment of cataract. KEY BENEFITS This report provides an extensive analysis of the current and emerging market trends and dynamics in the global intraocular lens market. This study provides the competitive landscape of the global market to predict the competitive environment across geographies. This report entails the detailed quantitative analysis of the current trends and future estimations to identify the prevailing opportunities. Comprehensive analysis of factors that drive and restrict the market growth is provided in the report. Region- and country-wise analysis is provided to understand the market trends and dynamics. KEY MARKET SEGMENTS By Type Monofocal Intraocular Lens Premium Intraocular Lens Toric Intraocular Lens Multifocal Intraocular Lens Accommodating Intraocular Lens Others Blue Light Filtering Intraocular Lens Phakic Intraocular Lens Aspheric Intraocular Lens By Material Polymethylmethacrylate (PMMA) Silicone Hydrophobic Acrylic By End User Hospitals Ambulatory Surgery Centers Ophthalmology Clinics Eye Research Institutes By Region North America U.S. Canada Mexico Europe Germany France UK Italy Spain Netherlands Norway Russia Sweden Switzerland Rest of Europe Asia-Pacific Japan China India Australia South Korea New Zealand Taiwan Thailand Rest of Asia-Pacific LAMEA Brazil Saudi Arabia South Africa Chile Columbia Egypt Iran Israel Turkey Venezuela Download the full report: https://www.reportbuyer.com/product/4883720/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/multiplex-assays-market---global-opportunity-analysis-and-industry-forecast-2014-2022-300455547.html


On Monday, shares in San Diego, California headquartered Organovo Holdings Inc. recorded a trading volume of 549,433 shares. The stock ended the session 0.37% higher at $2.72. The Company's shares are trading 7.62% below their 50-day moving average. Moreover, shares of Organovo, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have a Relative Strength Index (RSI) of 42.98. On May 01st, 2017, Organovo announced a collaboration with the University of Virginia (UVA) to develop 3D bioprinted tissues for volumetric muscle loss injury. The research will take place in the laboratory of George J. Christ, Ph.D., professor of biomedical engineering and orthopaedic surgery at UVA. The free research report on ONVO is available at: San Diego, California headquartered DexCom Inc.'s stock closed the day 3.69% lower at $73.40. A total volume of 2.17 million shares was traded, which was above their three months average volume of 937,590 shares. The Company's shares have advanced 22.95% since the start of this year. The stock is trading 6.56% below its 50-day moving average. Additionally, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 41.31. On May 03rd, 2017, research firm Canaccord Genuity reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $95 a share to $90 a share. On May 04th, 2017, DexCom announced that its G5 Mobile CGM System can now be used with Apple Watches throughout Europe by downloading the latest version of the G5 Mobile App - iOS 1.6. By adding Apple Watch as another display device, Europeans living with diabetes have even more options to view their glucose readings and alerts on Dexcom's G5 Mobile CGM System to help better manage their diabetes. The complimentary report on DXCM can be downloaded at: Shares in Madison, New Jersey headquartered Quest Diagnostics Inc. recorded a trading volume of 703,163 shares. The stock ended yesterday's trading session 0.09% higher at $107.19. The Company's shares have advanced 9.53% in the past month, 16.06% in the previous three months, and 17.75% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.40% and 19.47%, respectively. Furthermore, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 78.18. On April 26th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $110 a share to $115 a share. On May 01st, 2017, Quest Diagnostics announced that its senior Vice President and Chief Information Officer, Lidia L. Fonseca, has received a 2017 Forbes CIO Innovation Award. The award, presented during the Forbes Innovation Summit on April 24th, 2017, recognizes CIOs of multibillion-dollar companies who have demonstrated the ability to generate value through innovation. Visit us today and download our complete research report on DGX for free at: Burlington, North Carolina headquartered Laboratory Corp. of America Holdings' ("LabCorp®") stock finished Monday's session 0.13% lower at $142.19 with a total trading volume of 499,035 shares. The Company's shares have advanced 9.49% over the previous three months and 10.76% since the start of this year. The stock is trading above its 200-day moving average by 4.81%. Additionally, shares of Laboratory Corp., which operates as an independent clinical laboratory company worldwide, have an RSI of 50.73. On May 04th, 2017, LabCorp® has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services and Catholic Health Initiatives. With the acquisition, LabCorp assumes PAML's ownership interests in several joint ventures: Colorado Laboratory Services, Kentucky Laboratory Services, MountainStar Clinical Laboratories, PACLAB Network Laboratories, and Tri-Cities Laboratory.  Get free access to your technical report on LH at: Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. SC has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Specimen Testing is Now Commercially Available in the Clinical Laboratories of Helomics Corporation PITTSBURGH, PA and WEST PALM BEACH, FL / ACCESSWIRE / May 11, 2017 / Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotechnology industries, and MDNA Life Sciences, Inc. (MDNA), the molecular diagnostics company pioneering the development of liquid biopsy tests based on the mitochondrial genome, today announced the commercial launch of MDNA's liquid biopsy Prostate Mitomic Test™ (PMT™) in selected U.S. markets. This proprietary test, which utilizes MDNA's Mitomic Technology™ platform, exploits the unique biological characteristics of mitochondrial DNA and is available exclusively in the clinical laboratories of Helomics. PMT™ is a liquid biopsy test independent of PSA and age for the early detection of high-grade prostate cancer in advance of biopsy. It is intended for use in men with clinical suspicion of prostate cancer to determine who is likely to have high-grade cancer that may require immediate intervention. PMT's high negative predictive value will also be useful in identifying cases that can safely delay or forego immediate biopsy. Current clinical practice using PSA as a first-line screening tool results in many unnecessary biopsies. PMT™ aids clinicians in differentiating between men who will benefit from immediate biopsy from those who will not, thus avoiding a costly and invasive procedure. Gerald J. Vardzel Jr., President and CEO of Helomics, said, "We are extremely excited about the launch of the first clinical test commercialized as a result of our strategic collaboration with MDNA. We are very pleased that MDNA has chosen us to be their commercialization partner and we are looking forward to collaborating with them to bring additional diagnostic tests, based on their proprietary mitochondrial DNA platform, to the market." Arlette H. Uihlein, MD, FACP, FASCP, Vice President of Operations, Pathology Services, and Medical Director at Helomics added, "As the leading developer of mitochondrial DNA-based diagnostic tests, MDNA's proprietary Mitomic Technology™ platform is uniquely positioned to mine mitochondrial DNA for unique biomarkers of disease. The identification of these mitochondrial DNA biomarkers in the blood of patients, and the validation of their clinical utility, will have a significant diagnostic impact across a wide variety of different disease states." Chris Mitton, President and CEO of MDNA, stated, "We are pleased to announce the availability of PMT™ as an LDT through the Helomics' clinical lab. This is a key milestone for the commercial expansion of this novel test and for our proprietary Mitomic Technology™ platform. With a 97% negative predictive value for high-grade prostate cancer, PMT™ will have a significant impact on how prostate biopsy decisions are made moving forward, and we are excited to be working with Helomics to increase patient access to this technology in the U.S. This is the first of several proprietary liquid biopsy tests that we plan to commercialize leveraging the Mitomic Technology™ platform through our strategic collaboration with Helomics. Tests currently in development include a new groundbreaking liquid biopsy test for endometriosis, as well as blood-based tests for ovarian cancer and lung cancer." Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. Helomics offers advanced clinical laboratory diagnostic tests as well as scientific and non-scientific product enhancement services to provide a customized solution to our client's specific product development needs. Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information please visit: www.helomics.com. MDNA Life Sciences, Inc. is leading the development of molecular diagnostic tests using its proprietary Mitomic Technology™ platform that exploits the unique biological characteristics of mitochondrial DNA. This innovative platform is a highly attractive and effective system for biomarker discovery, early disease detection, monitoring, risk assessment and therapeutic targeting. It has led to the discovery of numerous novel and proprietary biomarkers for a multitude of cancers and other diseases. The Company is applying its expertise in mitochondrial genomics to develop an extensive and proprietary portfolio of blood-based molecular tests for conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. For more information, visit www.mdnalifesciences.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. For more information regarding Helomics Corporation, please contact: For more information regarding MDNA Life Sciences, Inc., please contact: Specimen Testing is Now Commercially Available in the Clinical Laboratories of Helomics Corporation PITTSBURGH, PA and WEST PALM BEACH, FL / ACCESSWIRE / May 11, 2017 / Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotechnology industries, and MDNA Life Sciences, Inc. (MDNA), the molecular diagnostics company pioneering the development of liquid biopsy tests based on the mitochondrial genome, today announced the commercial launch of MDNA's liquid biopsy Prostate Mitomic Test™ (PMT™) in selected U.S. markets. This proprietary test, which utilizes MDNA's Mitomic Technology™ platform, exploits the unique biological characteristics of mitochondrial DNA and is available exclusively in the clinical laboratories of Helomics. PMT™ is a liquid biopsy test independent of PSA and age for the early detection of high-grade prostate cancer in advance of biopsy. It is intended for use in men with clinical suspicion of prostate cancer to determine who is likely to have high-grade cancer that may require immediate intervention. PMT's high negative predictive value will also be useful in identifying cases that can safely delay or forego immediate biopsy. Current clinical practice using PSA as a first-line screening tool results in many unnecessary biopsies. PMT™ aids clinicians in differentiating between men who will benefit from immediate biopsy from those who will not, thus avoiding a costly and invasive procedure. Gerald J. Vardzel Jr., President and CEO of Helomics, said, "We are extremely excited about the launch of the first clinical test commercialized as a result of our strategic collaboration with MDNA. We are very pleased that MDNA has chosen us to be their commercialization partner and we are looking forward to collaborating with them to bring additional diagnostic tests, based on their proprietary mitochondrial DNA platform, to the market." Arlette H. Uihlein, MD, FACP, FASCP, Vice President of Operations, Pathology Services, and Medical Director at Helomics added, "As the leading developer of mitochondrial DNA-based diagnostic tests, MDNA's proprietary Mitomic Technology™ platform is uniquely positioned to mine mitochondrial DNA for unique biomarkers of disease. The identification of these mitochondrial DNA biomarkers in the blood of patients, and the validation of their clinical utility, will have a significant diagnostic impact across a wide variety of different disease states." Chris Mitton, President and CEO of MDNA, stated, "We are pleased to announce the availability of PMT™ as an LDT through the Helomics' clinical lab. This is a key milestone for the commercial expansion of this novel test and for our proprietary Mitomic Technology™ platform. With a 97% negative predictive value for high-grade prostate cancer, PMT™ will have a significant impact on how prostate biopsy decisions are made moving forward, and we are excited to be working with Helomics to increase patient access to this technology in the U.S. This is the first of several proprietary liquid biopsy tests that we plan to commercialize leveraging the Mitomic Technology™ platform through our strategic collaboration with Helomics. Tests currently in development include a new groundbreaking liquid biopsy test for endometriosis, as well as blood-based tests for ovarian cancer and lung cancer." Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. Helomics offers advanced clinical laboratory diagnostic tests as well as scientific and non-scientific product enhancement services to provide a customized solution to our client's specific product development needs. Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information please visit: www.helomics.com. MDNA Life Sciences, Inc. is leading the development of molecular diagnostic tests using its proprietary Mitomic Technology™ platform that exploits the unique biological characteristics of mitochondrial DNA. This innovative platform is a highly attractive and effective system for biomarker discovery, early disease detection, monitoring, risk assessment and therapeutic targeting. It has led to the discovery of numerous novel and proprietary biomarkers for a multitude of cancers and other diseases. The Company is applying its expertise in mitochondrial genomics to develop an extensive and proprietary portfolio of blood-based molecular tests for conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. For more information, visit www.mdnalifesciences.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. For more information regarding Helomics Corporation, please contact: For more information regarding MDNA Life Sciences, Inc., please contact:


Specimen Testing is Now Commercially Available in the Clinical Laboratories of Helomics Corporation PITTSBURGH, PA and WEST PALM BEACH, FL / ACCESSWIRE / May 11, 2017 / Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotechnology industries, and MDNA Life Sciences, Inc. (MDNA), the molecular diagnostics company pioneering the development of liquid biopsy tests based on the mitochondrial genome, today announced the commercial launch of MDNA's liquid biopsy Prostate Mitomic Test™ (PMT™) in selected U.S. markets. This proprietary test, which utilizes MDNA's Mitomic Technology™ platform, exploits the unique biological characteristics of mitochondrial DNA and is available exclusively in the clinical laboratories of Helomics. PMT™ is a liquid biopsy test independent of PSA and age for the early detection of high-grade prostate cancer in advance of biopsy. It is intended for use in men with clinical suspicion of prostate cancer to determine who is likely to have high-grade cancer that may require immediate intervention. PMT's high negative predictive value will also be useful in identifying cases that can safely delay or forego immediate biopsy. Current clinical practice using PSA as a first-line screening tool results in many unnecessary biopsies. PMT™ aids clinicians in differentiating between men who will benefit from immediate biopsy from those who will not, thus avoiding a costly and invasive procedure. Gerald J. Vardzel Jr., President and CEO of Helomics, said, "We are extremely excited about the launch of the first clinical test commercialized as a result of our strategic collaboration with MDNA. We are very pleased that MDNA has chosen us to be their commercialization partner and we are looking forward to collaborating with them to bring additional diagnostic tests, based on their proprietary mitochondrial DNA platform, to the market." Arlette H. Uihlein, MD, FACP, FASCP, Vice President of Operations, Pathology Services, and Medical Director at Helomics added, "As the leading developer of mitochondrial DNA-based diagnostic tests, MDNA's proprietary Mitomic Technology™ platform is uniquely positioned to mine mitochondrial DNA for unique biomarkers of disease. The identification of these mitochondrial DNA biomarkers in the blood of patients, and the validation of their clinical utility, will have a significant diagnostic impact across a wide variety of different disease states." Chris Mitton, President and CEO of MDNA, stated, "We are pleased to announce the availability of PMT™ as an LDT through the Helomics' clinical lab. This is a key milestone for the commercial expansion of this novel test and for our proprietary Mitomic Technology™ platform. With a 97% negative predictive value for high-grade prostate cancer, PMT™ will have a significant impact on how prostate biopsy decisions are made moving forward, and we are excited to be working with Helomics to increase patient access to this technology in the U.S. This is the first of several proprietary liquid biopsy tests that we plan to commercialize leveraging the Mitomic Technology™ platform through our strategic collaboration with Helomics. Tests currently in development include a new groundbreaking liquid biopsy test for endometriosis, as well as blood-based tests for ovarian cancer and lung cancer." Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. Helomics offers advanced clinical laboratory diagnostic tests as well as scientific and non-scientific product enhancement services to provide a customized solution to our client's specific product development needs. Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information please visit: www.helomics.com. MDNA Life Sciences, Inc. is leading the development of molecular diagnostic tests using its proprietary Mitomic Technology™ platform that exploits the unique biological characteristics of mitochondrial DNA. This innovative platform is a highly attractive and effective system for biomarker discovery, early disease detection, monitoring, risk assessment and therapeutic targeting. It has led to the discovery of numerous novel and proprietary biomarkers for a multitude of cancers and other diseases. The Company is applying its expertise in mitochondrial genomics to develop an extensive and proprietary portfolio of blood-based molecular tests for conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. For more information, visit www.mdnalifesciences.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. For more information regarding Helomics Corporation, please contact: For more information regarding MDNA Life Sciences, Inc., please contact:


Specimen Testing is Now Commercially Available in the Clinical Laboratories of Helomics Corporation PITTSBURGH, PA and WEST PALM BEACH, FL / ACCESSWIRE / May 11, 2017 / Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotechnology industries, and MDNA Life Sciences, Inc. (MDNA), the molecular diagnostics company pioneering the development of liquid biopsy tests based on the mitochondrial genome, today announced the commercial launch of MDNA's liquid biopsy Prostate Mitomic Test™ (PMT™) in selected U.S. markets. This proprietary test, which utilizes MDNA's Mitomic Technology™ platform, exploits the unique biological characteristics of mitochondrial DNA and is available exclusively in the clinical laboratories of Helomics. PMT™ is a liquid biopsy test independent of PSA and age for the early detection of high-grade prostate cancer in advance of biopsy. It is intended for use in men with clinical suspicion of prostate cancer to determine who is likely to have high-grade cancer that may require immediate intervention. PMT's high negative predictive value will also be useful in identifying cases that can safely delay or forego immediate biopsy. Current clinical practice using PSA as a first-line screening tool results in many unnecessary biopsies. PMT™ aids clinicians in differentiating between men who will benefit from immediate biopsy from those who will not, thus avoiding a costly and invasive procedure. Gerald J. Vardzel Jr., President and CEO of Helomics, said, "We are extremely excited about the launch of the first clinical test commercialized as a result of our strategic collaboration with MDNA. We are very pleased that MDNA has chosen us to be their commercialization partner and we are looking forward to collaborating with them to bring additional diagnostic tests, based on their proprietary mitochondrial DNA platform, to the market." Arlette H. Uihlein, MD, FACP, FASCP, Vice President of Operations, Pathology Services, and Medical Director at Helomics added, "As the leading developer of mitochondrial DNA-based diagnostic tests, MDNA's proprietary Mitomic Technology™ platform is uniquely positioned to mine mitochondrial DNA for unique biomarkers of disease. The identification of these mitochondrial DNA biomarkers in the blood of patients, and the validation of their clinical utility, will have a significant diagnostic impact across a wide variety of different disease states." Chris Mitton, President and CEO of MDNA, stated, "We are pleased to announce the availability of PMT™ as an LDT through the Helomics' clinical lab. This is a key milestone for the commercial expansion of this novel test and for our proprietary Mitomic Technology™ platform. With a 97% negative predictive value for high-grade prostate cancer, PMT™ will have a significant impact on how prostate biopsy decisions are made moving forward, and we are excited to be working with Helomics to increase patient access to this technology in the U.S. This is the first of several proprietary liquid biopsy tests that we plan to commercialize leveraging the Mitomic Technology™ platform through our strategic collaboration with Helomics. Tests currently in development include a new groundbreaking liquid biopsy test for endometriosis, as well as blood-based tests for ovarian cancer and lung cancer." Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. Helomics offers advanced clinical laboratory diagnostic tests as well as scientific and non-scientific product enhancement services to provide a customized solution to our client's specific product development needs. Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information please visit: www.helomics.com. MDNA Life Sciences, Inc. is leading the development of molecular diagnostic tests using its proprietary Mitomic Technology™ platform that exploits the unique biological characteristics of mitochondrial DNA. This innovative platform is a highly attractive and effective system for biomarker discovery, early disease detection, monitoring, risk assessment and therapeutic targeting. It has led to the discovery of numerous novel and proprietary biomarkers for a multitude of cancers and other diseases. The Company is applying its expertise in mitochondrial genomics to develop an extensive and proprietary portfolio of blood-based molecular tests for conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. For more information, visit www.mdnalifesciences.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. For more information regarding Helomics Corporation, please contact: For more information regarding MDNA Life Sciences, Inc., please contact:


Research and Markets has announced the addition of the "Spectroscopy Equipment and Accessories - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Spectroscopy Equipment and Accessories in US$ Thousand by the following Product Segments: The report profiles 117 companies including many key and niche players such as: 1. OUTLOOK A Prelude Overview Current and Future Analysis Sustained Growth for Aftermarket Products and Services 2. MARKET OVERVIEW Government Funding and Research Activities Propel Molecular Spectroscopy Market Growing Preference for Handheld Instruments Infrared Spectroscopy - A Peek into Technology and Application Trends Raman Spectroscopy - A Review of Advanced Technologies and Applications Tip-enhanced Raman Spectroscopy (TERS) Surface-enhanced Raman Spectroscopy (SERS) Spatially Offset Raman Spectroscopy (SORS) Magnetic Photoacoustoic Raman (MPR) Raman Spectroscopy Emerges as Attractive Analytical Tool for Pharmaceutical Industry Fluorescence Spectroscopy - A Gold Standard Technology Atomic Spectroscopy - An Overview Mass Spectrometry: Technological Developments and Expanding End-Use Applications to Bolster Growth Review of Select MS Technologies The Way Ahead for FT-MS and Magnetic Sector MS Technologies Portability: A Major Driving Force for MS Systems Market Nanotube Coating to Enable Miniaturization in Mass Spectrometers High Prices of MS Systems Hold Down Sales Growth Purpose-Built Mass Spectrometers to Transform Personalized Medicine Leading End Users of Mass Spectrometry Devices A Peek into Regulatory and Competitive Landscape in MS Ion-Trap Mass Spectrometry Technology Losses Sheen Reduced Government Spending on Laboratory Testing Lack of Suitable Software and Diversity of MS Systems - A Major Challenge Smaller Clinical Laboratories Continue to Shy Away from Mass Spectrometers 3. MARKET TRENDS & ISSUES Rise in Drug Development Outsourcing to Fuel Global Spectroscopy Market Growing Significance of Miniaturization in Spectroscopy Shift of Analytical Instruments Industry to Mass Customization Improved Mobility Broadens the Role of Spectroscopy Improved Analyzer Reliability and Performance Hyphenated Technologies Exhibit Growth Spectroscopy Makes Inroads into Novel Applications Applications Extend to Defense and Civilian Areas Atomic and Molecular Spectrometers Benefit from Technological Improvements Demand for Used Spectroscopy Instruments to Grow Robustly in Future 4. COMPETITIVE LANDSCAPE Competition in the Spectrometry Market: An Insight Molecular Spectroscopy: A Highly Fragmented Market List of Leading Players in the Global Molecular Spectroscopy Market by Product Type Atomic Spectroscopy Market List of Leading Players in the Global Atomic Spectroscopy Market Mass Spectrometry Market List of Leading Players in the Global Mass Spectrometry Market 5. PRODUCT OVERVIEW Spectroscopy Spectrophotometer Fluorometer Different Types of Spectrophotometry Analysis Infrared Spectrophotometry Near-Infrared Spectrophotometry Visible Spectrophotometry Ion Mobility Spectrometry Color Spectrophotometry Near-Ultraviolet Spectrophotometry Spectrometry Spectrometers: A Broad Spectrum of Devices A. Molecular Spectroscopy - The Study of Absorption of Light by Molecules Ultraviolet/Visible (UV/VIS) Spectroscopy Raman Spectroscopy Nuclear Magnetic Resonance (NMR) Spectrometers Near Infrared (NIR) Spectroscopy Applications of Near-IR Techniques Process Analysis Applications of the NIR Spectroscopy Infrared Spectroscopy Fourier-Transform Infrared (FTIR) Spectroscopy B. Atomic Spectroscopy Arc/Spark Spectrometry ICP and ICP-MS Atomic Absorption Spectroscopy Atomic Absorption Analysis Instrumentation Atomizers Double Beam Systems Applications Trends and Future Developments X-Ray Fluorescence Spectrometers (XRF) C. Mass Spectrometry (MS) Mass Spectrometer Types of Mass Spectrometers and their Applications Liquid Chromatography-Mass Spectrometry (LC-MS) Gas Chromatography-Mass Spectrometry (GC-MS) MALDI-TOF Fluorescence Spectroscopy - An Overview Biomedical Applications of Fluorescence Spectroscopy Fluorescence Quenching Fluorescence Polarization Resonance Energy Transfer Filter Fluorimeters Spectrofluorimeters Monochromators Fluorescence-Lifetime Measurements 6. PRODUCT INNOVATIONS/INTRODUCTIONS Shimadzu Launches LCMS-8045 Mass Spectrometer in Europe JUKI Group Commercializes AY555 Spectrophotometer Avantes Launches AvaSpec-Hero Sensline Spectrometer Agilent Launches New 4210 Microwave Plasma-Atomic Emission Spectrometer Princeton Launches FERGIE Spectroscopy System Konica Minolta Introduces Automobile Specific Spectrophotometers, CM-25cG and CM-M6 Shimadzu Launches New GC-MS/MS System, GCMS-TQ8050 Datacolor Introduces Datacolor 20D for Paint Retailers StellarNet Launches Portable Research Grade Raman Spectroscopy System Jenway® Launches New Visible Scanning Spectrophotometer, 7200 IRsweep to Launch IRspectrometer Shimadzu Introduces Atomic Absorption Spectrophotometer, AA-6880F Bruker Launches timsTOF System Thermo Fisher Launches New Spectrometry Devices Techkon Launches Continuous Scanning Spectrophotometer, SpectroEdge ES7500 Sciex Introduces SCIEX QTRAP® 6500+ LC-MS/MS System StellarNet Launches RED-Wave-NIRX-SR Spectrometer Thermo Scientific Launches NanoDrop One Spectrophotometers Thermo Scientific Launches GENESYS 30 Visible-Range Spectrophotometer Thermo Scientific Launches New DXR2 Line of Raman Microscopes Bruker Launches Total Reflection X-Ray Fluorescence Spectrometer, S4 TStar Agilent Launches 5110 ICP-OES Magritek Introduces 60 MHz Benchtop NMR Spectrometers, Spinsolve 60 Thermo Scientific Launches New FT-NIR Spectrometer, Nicolet iS5N Rigaku Launches New Benchtop Variable Spot EDXRF Spectrometer, Rigaku NEX DE Advion Introduces TIDES EXPRESS Merck Introduces Spectroquant® Prove Spectrophotometers Shimadzu Introduces Inductively Coupled Plasma Mass Spectrometer, ICPMS-2030 AQULABO Group Introduces Uviline 9300 and Uviline 9600 Rigaku Launches Rigaku ZSX Primus IV StellarNet BLUE-Wave Compact Spectrometers Line SPECTRO Introduces New Line of SPECTRO XEPOS Spectrometers Thermo Fisher Introduces Thermo Scientific 253 Ultra HR-IRMS StellarNet Launches BLACK-Comet-HR Specac Introduces Pearl Liquid Analysis Accessory Agilent Introduces Agilent 5977B HES GC/MSD System in China Datacolor Introduces New Line of Color Measurement Spectrophotometers Bruker Introduces HH-LIBS Device, EOS 500 Bruker Launches 10 kHz rapifleX MALDI-TOF/TOF Mass Spectrometer Konica Minolta Introduces Auto-Scanning Spectrophotometer, FD-9 Rigaku Introduces Rigaku NANOHUNTER II TXRF Spectrometer SPECTRO Introduces New SPECTROLAB Arc/Spark Optical Emission Spectrometers SPECTRO Introduces SPECTROSCOUT X-ray Fluorescence Spectrometer Bruker Introduces S2 PUMA Shimadzu Introduces Shimadzu LCMS-8060 Triple Quadrupole Mass Spectrometer Thermo Scientific Launches Orbitrap Fusion Lumos Tribrid Mass Spectrometer Agilent Introduces Agilent 6470 Triple Quadrupole LC/MS Waters Introduces Vion IMS QTof Mass Spectrometer DeNovix Introduces DS-11 FX+ Spectrophotometer / Fluorometer Agilent Launches Agilent 6545 Q-TOF Mass Spectrometry System Implen Introduces Fourth Generation NanoPhotometer® Spectrophotometers Shimadzu Corporation Compact Monochromator System Package, SPG-120-REV JEOL Develops JPS-9030, X-ray Photoelectron Spectrometer Datacolor Introduces CHECK 3 Portable Spectrophotometer SPECTRO Launches SPECTRO xSort Handheld EDXRF Spectrometers Bruker Handheld Raman Spectrometer, BRAVO Shimadzu Launches RF-6000 Spectrofluorophotometer X-Rite Introduces X-Rite Ci7800 and X-Rite Ci7600 SPECTRO Introduces SPECTRO xSORT Line of Handheld EDXRF Spectrometers Analytik Jena Introduces New ICP-MS Products, PlasmaQuant® MS and PlasmaQuant® MS Elite Ocean Optics Introduces New Miniature Spectrometer, Flame Shimadzu Launches UV1280 UVVIS Spectrophotometer in the US SPECTRO Introduces SPECTRO ARCOS High-Resolution Spectrometer JEOL Launches JMS-T200GC High-end GC-TOFMS Thermo Scientific Launches Orbitrap Based Q Exactive Focus LC MS/MS Mass Spectrometer 7. RECENT INDUSTRY ACTIVITY Bruker Acquires Active Spectrum Inc. Wasatch Photonics Acquires Process Raman Spectroscopy Technology from Mustard Tree Instruments Shimadzu Institutes Shimadzu China Mass Spectrometry Center INSION Enters into Distribution Agreement with Digilab - The United States (75) - Canada (2) - Japan (11) - Europe (40) - France (3) - Germany (11) - The United Kingdom (18) - Italy (1) - Spain (1) - Rest of Europe (6) - Asia-Pacific (Excluding Japan) (9) - Middle East (1) For more information about this report visit http://www.researchandmarkets.com/research/gxbsmg/spectroscopy


BURLINGTON, N.C. & RENTON, Wash. & ENGLEWOOD, Colo.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), Providence Health & Services (Providence) and Catholic Health Initiatives (CHI), today announced that they have entered into a definitive agreement for LabCorp to acquire all of the ownership interest in Pathology Associates Medical Laboratories, LLC, (PAML), one of the nation’s premier medical reference laboratories and a healthcare solutions company jointly owned by Providence and CHI. In addition to PAML, LabCorp will also acquire PAML’s interest in the following joint ventures: Colorado Laboratory Services (CLS), Kentucky Laboratory Services (KLS), MountainStar Clinical Laboratories (MSCL), PACLAB Network Laboratories (PACLAB) and Tri-Cities Laboratory (TCL). “This signature transaction strengthens LabCorp’s relationships with anchor health systems and expands LabCorp’s geographic presence into important markets,” said David P. King, chairman and chief executive officer, LabCorp. “We have always admired the commitment of PAML, its owners and its joint venture partners to providing high-quality, community-based laboratory services. LabCorp shares that same vision and commitment, and is excited to work with these industry-leading health systems and hospitals as partners to continue to provide these services.” Headquartered in Spokane, Washington, PAML and its joint ventures provide laboratory services in California, Colorado, Idaho, Kentucky, Montana, Oregon, Utah and Washington. PAML is an industry leader in joint venture partnerships with community-based hospitals. The transactions involving PAML and the PAML-affiliated joint ventures expand LabCorp’s geographic scope in the Pacific Northwest, Midwest and South. LabCorp currently provides services to several Swedish Medical Center facilities in Seattle, a partner within the Providence system. “We are proud of the high-quality service PAML and its joint ventures have provided,” said Mike Butler, president of operations, chief executive, Providence Health & Services. “We routinely evaluate how to best deliver health care services to the communities we serve and LabCorp will continue to meet the rapidly changing needs of patients and providers.” In addition, the hospital co-owners of CLS, based in Lakewood, Colorado; KLS, based in Lexington, Kentucky; and PACLAB Network Laboratories, based in Renton, Washington; have all agreed to sell their joint venture interests to LabCorp. The hospital partners in MSCL, based in Salt Lake City, Utah, and in TCL, based in Kennewick, Washington, continue to evaluate future options for their ownership of the joint venture, which may include a sale to LabCorp. The hospital co-owner of Alpha Medical Laboratory (Alpha), a PAML-affiliated joint venture based in Coeur d’Alene, Idaho, intends to acquire PAML’s interest in Alpha; after which it will sell the joint venture assets to LabCorp upon final board approval. After the staged transactions are complete, Providence, CHI and the hospital joint venture owners will continue to provide all existing in-patient hospital laboratory services. LabCorp will then continue to provide the outreach testing services and reference laboratory services currently provided by PAML and the joint ventures that are part of the overall transactions. The transactions do not include any PAML joint venture services in California. “As part of our mission, CHI is focused on building healthier communities. This goal guides our business decisions in the constantly changing dynamics and demands of health care today,” said Kevin Lofton, CEO, Catholic Health Initiatives. “We are confident that our selection of LabCorp to be PAML’s new owner will serve the best interests of all who rely on us to meet their health care needs through comprehensive, high quality laboratory services.” The transactions are subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The parties anticipate that transaction closings will begin in 2017 and continue into 2018. There will be no changes to operations or services at PAML or the joint ventures until the applicable transaction is complete. The organizations will work together to plan and implement a smooth, thoughtful transition that maintains continuity of services for patients, hospitals, clients and clinicians while providing direct access to the additional capabilities of LabCorp. Other terms of the transactions were not disclosed and no additional information is available at this time. Providence Health & Services is committed to improving the health of the communities it serves, especially for those who are poor and vulnerable. In 2016, Providence provided nearly $1.2 billion in community benefit to help meet the needs of its communities, both today and into the future. Providence Health & Services is a part of Providence St. Joseph Health, a family of organizations that includes 50 hospitals, 829 physician clinics, senior services, supportive housing and many other health and educational services. The health system and its partners employ more than 100,000 caregivers serving communities across seven states – Alaska, California, Montana, New Mexico, Oregon, Texas and Washington. Along with Saint Joseph Health, PSJH includes: in Texas, Covenant Health and Covenant Medical Group; in California, Facey Medical Foundation, Hoag Memorial Hospital Presbyterian and St. Joseph Heritage Healthcare; and in Washington, Kadlec Regional Medical Center, Pacific Medical Centers and Swedish Health Services. Catholic Health Initiatives, a nonprofit, faith-based health system formed in 1996 through the consolidation of four Catholic health systems, expresses its mission each day by creating and nurturing healthy communities in the hundreds of sites across the nation where we provide care. The nation’s third-largest nonprofit health system, Englewood, Colorado-based CHI operates in 18 states and comprises 103 hospitals, including four academic medical centers and major teaching hospitals as well as 30 critical-access facilities; community health-services organizations; accredited nursing colleges; home-health agencies; senior living communities; and other facilities and services that span the inpatient and outpatient continuum of care. In fiscal year 2016, CHI provided more than $1.1 billion in financial assistance and community benefit – a 13% increase over the previous year -- for programs and services for the poor, free clinics, education and research. Financial assistance and community benefit totaled more than $2 billion with the inclusion of the unpaid costs of Medicare. The health system, which generated operating revenues of $15.9 billion in fiscal year 2016, has total assets of approximately $22.7 billion. Laboratory Corporation of America® Holdings (NYSE: LH), an S&P 500 company, is a world leading life sciences company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to provide better care. With net revenue in excess of $9 billion in 2016, LabCorp’s 50,000 employees serve clients in 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com. This press release contains forward-looking statements including with respect to LabCorp’s (the Company) estimated 2017 guidance and the impact of various factors on operating and financial results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect LabCorp’s operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2015, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2015, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.


News Article | February 17, 2017
Site: www.prnewswire.co.uk

Revenue Prospects by Technology (Single, Ion Trap, Quadrupole, Hybrid, Triple Quadrupole, Q-TOF, FTMS), by Application (Academia, Biotech, Agriculture, CRO, Hospitals, Environmental, Materials) and Geography Mass spectrometry - our new study reveals trends, R&D progress, and predicted revenues Where is the mass spectrometry market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover how to stay ahead Our 183-page report provides 111 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing mass spectrometry market. See how to exploit the opportunities. Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market and 4 different segmentations, with 2 device types, 6 technologies and 7 applications To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com • Mass Spectrometry Market Forecasts to 2027, By Application: - Academia - Biotech and Biopharma - Agriculture - Contract Research Organisations - Hospitals/ Clinical Laboratories - Environmental Industry - Materials Industry In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 12 leading national markets: The report also includes profiles and forecasts for some of the leading companies in the mass spectrometry device market, with a focus on the mass spectrometry device segment of these companies' operations. There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market. Leading companies and the potential for market growth Overall world revenue for mass spectrometry will surpass $3.8bn in 2017, our work calculates. We predict strong revenue growth through to 2027. Market entry of continuous mass spectrometry devices and increasing prevalence of neurological conditions will increase sales to 2027. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the Mass Spectrometry Market report helps you In summary, our 183-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the world mass spectrometry market and 3 different segmentations, with 2 device types, 6 product categories and 7 applications - discover the industry's prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 4 regional markets and 12 of the leading national markets - North America: US, Canada, Europe: Germany, UK, France, Italy, Spain & Rest of Europe, APAC: Japan, China, Australia & New Zealand, India, & Rest of APAC and the Rest of the World • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight. Visiongain's study is for everybody needing commercial analyses for the mass spectrometry device market and leading companies. You find data, trends and predictions. Get our report today The Mass Spectrometry Market Forecast 2017-2027: Revenue Prospects by Technology (Single, Ion Trap, Quadrupole, Hybrid, Triple Quadrupole, Q-TOF, FTMS), by Application (Academia, Biotech, Agriculture, CRO, Hospitals, Environmental, Materials) and Geography. Avoid missing out - get our report now. To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com  or call Tel: +44(0)-20-7336-6100 To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Loading Clinical Laboratories collaborators
Loading Clinical Laboratories collaborators